ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Calcineurin"

  • 2019 American Transplant Congress

    Tacrolimus Concentration/Dose Ratio is an Independent Predictor of Death-Censored Kidney Allograft Survival

    T. Jouve1, J. Noble1, X. Fonrose2, B. Janbon1, G. Fiard3, P. Malvezzi1, L. Rostaing1

    1Nephrology, Dialysis, Aphereses and Transplantation Department, Grenoble University Hospital, Grenoble, France, 2Pharmacology, Pharmacogenetics and Toxicology Laboratory, Grenoble University Hospital, Grenoble, France, 3Urology and Kidney Transplantation Department, Grenoble University Hospital, Grenoble, France

    *Purpose: Tacrolimus (Tac) remains the cornerstone of kidney transplantation immunosuppression. Its narrow therapeutic index demands therapeutic drug monitoring. The C/D ratio (Tac trough concentration /…
  • 2019 American Transplant Congress

    Conversion from Tacrolimus Immediate Release to Tacrolimus Extended Release (Envarsus XR®): A Real World Cohort Highlighting Dosing Variability among Patients

    K. D. Belfield1, D. Malhotra2, M. Waleed3, E. A. Cohen1

    1Department of Pharmacy, Yale New Haven Hospital, New Haven, CT, 2Yale University School of Medicine, New Haven, CT, 3University of Connecticut School of Pharmacy, Storrs, CT

    *Purpose: Tacrolimus extended release (TacER) (Envarsus XR®) has become an attractive alternative to tacrolimus immediate release (TacIR) due to its once daily dosing scheme, favorable…
  • 2019 American Transplant Congress

    Belatacept Conversion for Calcineurin Inhibitor-Associated Thrombotic Microangiopathy in Kidney Transplant Recipients

    S. A. Muhsin, K. Safa, H. M. Gilligan, E. C. Heher, W. W. Williams, D. M. Wojciechowski

    Nephrology Division, MGH, Boston, MA

    *Purpose: Thrombotic Microangiopathy (TMA) in kidney transplant recipients is a serious complication that can cause graft loss. It can be associated with immunosuppressive medications such…
  • 2018 American Transplant Congress

    End Stage Renal Disease after Face Transplant

    N. Shockcor,1 B. Buckingham,1 W. Hassanein,1 A. Haririan,1 S. Roberts,2 A. Nam,1 E. Rodriguez,3 S. Bartlett,1 R. Barth.1

    1University of Maryland, Baltimore, MD; 2Ochsner Health Center, Covington, LA; 3New York University, New York, NY.

    Purpose Renal failure as an outcome of chronic immunosuppression is a known complication of organ transplantation. We report the first case of end stage renal…
  • 2018 American Transplant Congress

    High Calcineurin Inhibitor Intra Patient Variability is Associated with Early Renal Allograft Inflammation, Chronicity and Loss

    A. Sharma,1 A. Cherukuri,2 R. Mehta,1 P. Sood,1 S. Hariharan.1

    1Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA; 2Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA.

    High CNI IPV has been associated with poor kidney allograft outcomes, albeit in small limited studies. We evaluated effect of CNI IPV (the degree of…
  • 2018 American Transplant Congress

    New Onset Diabetes after Kidney Transplant: Comparisons of Risks Associated with Various Steroid-Containing Calcineurin Inhibitor and Sirolimus Regimens

    A. Santos, Jr.,1 M. Casey,1 K. Alquadan,1 X. Wen,2 C. Chen,3 A. Gutierrez-Mena,1 K. Womer.1

    1College of Medicine, Univ. of Florida, Gainesville, FL; 2College of Pharmacy, Univ. of Rhode Island, Kingston, RI; 3College of Pharmacy, Univ. of Florida, Gainesville, FL.

    INTRODUCTION: We aimed to examine the risk of new onset diabetes after transplant (NODAT) associated with the following maintenance immunosuppression regimens in kidney transplant recipients…
  • 2018 American Transplant Congress

    Single-Dose Basiliximab Induction in Liver Transplant Recipients with Delayed CNI Initiation

    D. Salerno,1 N. Lange,1 R. Rosenblatt,2 C. Sammons,3 B. Fortune.2

    1Pharmacy, NewYork-Presbyterian Hospital, New York, NY; 2Medicine, Weill Cornell Medicine, New York, NY; 3Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA.

    Liver transplant recipients (LTR) with peri-operative renal injury benefit from a delayed CNI protocol using basiliximab (IL2RA) induction to reduce early CNI exposure. Existing literature…
  • 2018 American Transplant Congress

    Tacrolimus Pharmacokinetics (PK) at Low, Medium, and High Trough Levels in Patients Converted from Twice-Daily Immediate-Release Tacrolimus (TacBID) to Once-Daily Extended-Release Tacrolimus (LCPT)

    P. Malvezzi,1 S. Bunnapradist,2 D. Stevens,3 M. Moten,3 A. Loh,3 S. Patel,3 L. Rostaing.1

    1Service De Néphrologie, Hémodialyse, Aphérèses Et Transplantation Rénale, Chu Grenoble Alpes, La Tronche, France; 2Nephrology, University of California, Los Angeles, Los Angeles, CA; 3Veloxis, Cary, NC.

    LCPT (Envarsus XR®) is a once-daily, extended-release formulation of tacrolimus which has demonstrated greater bioavailability and a smoother PK profile compared to TacBID. This post-hoc…
  • 2018 American Transplant Congress

    Outcomes in Liver Transplant Patients on Renal Sparing Protocol

    A. Polyak,1 D. Ganger,2 A. Shetty.2

    1New York Medical College, Valhalla, NY; 2Comprehensive Transplant Center, Northwestern University, Chicago, IL.

    As liver transplant outcomes have improved, long term native kidney function has taken a critical role in patient survival. Calcineurin inhibitors (CNIs), such as Tacrolimus…
  • 2018 American Transplant Congress

    Overexpression of BAX, NOL3, and XIAP Apoptotic Genes Participates in Calcineurin Inhibitors Nephrotoxicity: New Insights into Chronic Allograft Dysfunction

    L. Garcia-Covarrubias,1 G. Queipo,2 M. Fonseca,2 D. Alcantara,1 P. Prieto,1 H. Diliz,1 A. Garcia,1 H. Hinojosa,1 A. Cicero,1 G. Melendez,3 M. Alamilla,3 R. Lascurain,4 V. Soto.5

    1Transplantation, Hospital General de Mexico, Mexico City, Mexico; 2Genetics, Hospital General de Mexico, Mexico City, Mexico; 3Research, Hospital General de Mexico, Mexico City, Mexico; 4Faculty of Medicine, UNAM, Mexico City, Mexico; 5Pathology, Hospital General de Mexico, Mexico City, Mexico.

    Introduction: Calcineurin inhibitors toxicity (CNIT) is a factor that limit the outcome of renal transplantation graft. The hypoxia causes histological data as nodular hyalinosis, hyalinosis,…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 16
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences